Physician profile
Charles E Wilkinson
NPI 1386024875
$9,492.50
in general payments reported to CMS, 2019-2025
47 companies · $1,426 in 2025
The $1,426 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $1,841 · 2021: $1,484 · 2022: $1,146 · 2023: $1,245 · 2024: $1,532 · 2025: $1,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,202.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,561.30 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,259.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $847.34 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $651.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $593.85 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $586.93 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $483.79 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $481.52 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $379.40 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $314.79 | 2019-2024 | Jardiance, Tradjenta |
| Biohaven Pharmaceutical Holding Company Ltd. | $220.80 | 2022 | |
| Esperion Therapeutics, INC. | $184.35 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $166.40 | 2022-2025 | |
| Glaxosmithkline, LLC. | $155.85 | 2020-2025 | Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $146.04 | 2019-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Wilkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.